Literature DB >> 20142242

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

Erika A Waters1, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman.   

Abstract

BACKGROUND: Tamoxifen can reduce the risk of developing invasive estrogen receptor-positive breast cancer by 49%, but it is unknown how many women in the United States are taking tamoxifen for primary prevention of breast cancer.
METHODS: Data from the years 2000 and 2005 National Health Interview Surveys were analyzed to estimate the prevalence of tamoxifen use among U.S. women for primary chemoprevention of breast cancer.
RESULTS: In 2000, approximately 0.2% of U.S. women ages 40 to 79 years without a personal history of breast cancer took tamoxifen for chemoprevention (95% confidence interval, 0.13-0.31). In 2005, the prevalence was approximately 0.08% (95% confidence interval, 0.03-0.17).
CONCLUSION: The prevalence of tamoxifen use for primary prevention of breast cancer was very low in the years 2000 and 2005. Possible explanations for the low uptake are explored.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142242      PMCID: PMC3038785          DOI: 10.1158/1055-9965.EPI-09-0930

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  19 in total

1.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Authors:  Andrew N Freedman; Barry I Graubard; Sowmya R Rao; Worta McCaskill-Stevens; Rachel Ballard-Barbash; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2003-04-02       Impact factor: 13.506

Review 2.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Authors:  M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

3.  Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.

Authors:  Rebecca Taylor; Kenneth Taguchi
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.166

4.  Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Authors:  Joy Melnikow; Debora Paterniti; Rahman Azari; Christina Kuenneth; Stephen Birch; Miriam Kuppermann; James Nuovo; Janet Keyzer; Stuart Henderson
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

5.  Factors affecting breast cancer risk reduction practices among California physicians.

Authors:  Celia Patricia Kaplan; Jennifer S Haas; Eliseo J Pérez-Stable; Genevieve Des Jarlais; Steven E Gregorich
Journal:  Prev Med       Date:  2004-12-10       Impact factor: 4.018

6.  "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.

Authors:  Debora A Paterniti; Joy Melnikow; Jim Nuovo; Stuart Henderson; Michael DeGregorio; Miriam Kuppermann; Robert Nease
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

Review 7.  Overview of the main outcomes in breast-cancer prevention trials.

Authors:  J Cuzick; T Powles; U Veronesi; J Forbes; R Edwards; S Ashley; P Boyle
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

8.  Using a drug facts box to communicate drug benefits and harms: two randomized trials.

Authors:  Lisa M Schwartz; Steven Woloshin; H Gilbert Welch
Journal:  Ann Intern Med       Date:  2009-02-16       Impact factor: 25.391

9.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer.

Authors:  Karim Malek; Aliza K Fink; Soe Soe Thwin; Jerry Gurwitz; Patricia A Ganz; Rebecca A Silliman
Journal:  Med Care       Date:  2004-07       Impact factor: 2.983

View more
  67 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

2.  Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.

Authors:  Pascal Pujol; Christine Lasset; Pascaline Berthet; Catherine Dugast; Suzette Delaloge; Jean-Pierre Fricker; Isabelle Tennevet; Nathalie Chabbert-Buffet; Pascale This; Karen Baudry; Jerome Lemonnier; Lise Roca; Sylvie Mijonnet; Paul Gesta; Jean Chiesa; Helene Dreyfus; Philippe Vennin; Capucine Delnatte; Yves Jean Bignon; Alain Lortholary; Fabienne Prieur; Laurence Gladieff; Anne Lesur; Krishna B Clough; Catherine Nogues; Anne-Laure Martin
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

3.  Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Authors:  Laura L Reimers; Parijatham S Sivasubramanian; Dawn Hershman; Mary Beth Terry; Heather Greenlee; Julie Campbell; Kevin Kalinsky; Matthew Maurer; Ramona Jayasena; Rossy Sandoval; Maria Alvarez; Katherine D Crew
Journal:  Breast J       Date:  2015-04-16       Impact factor: 2.431

4.  Affective forecasting and medication decision making in breast-cancer prevention.

Authors:  Michael Hoerger; Laura D Scherer; Angela Fagerlin
Journal:  Health Psychol       Date:  2016-02-11       Impact factor: 4.267

5.  Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1.

Authors:  Christine M Gunn; Barbara G Bokhour; Victoria A Parker; Tracy A Battaglia; Patricia A Parker; Angela Fagerlin; Worta McCaskill-Stevens; Hanna Bandos; Sarah B Blakeslee; Christine Holmberg
Journal:  Med Decis Making       Date:  2019-02-25       Impact factor: 2.583

Review 6.  Suitable trial designs and cohorts for preventive breast cancer agents.

Authors:  Kathrin Strasser-Weippl; Paul E Goss
Journal:  Nat Rev Clin Oncol       Date:  2013-10-08       Impact factor: 66.675

7.  My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).

Authors:  Christine Holmberg; Erika A Waters; Katie Whitehouse; Mary Daly; Worta McCaskill-Stevens
Journal:  Med Decis Making       Date:  2015-07-16       Impact factor: 2.583

8.  Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk
Journal:  Breast       Date:  2014-12-06       Impact factor: 4.380

9.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Authors:  Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

Review 10.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.